Advances in Nephrology in 2020


The Nephrology and Transplantation Update Course is a highly anticipated and well attended pre-congress session of the Australian New Zealand Society of Nephrology (ANZSN) Annual Scientific Meeting that will provide an overview of evidence-based medicine in Nephrology in the past few years. The theme of this year course is Advances in Nephrology in 2020.

Healthcare is ever changing with new discoveries, breakthroughs and innovations that significantly transform Nephrology field and improve care for patients with kidney disease throughout the world. As we enter into a new decade, it is useful to pause and review some of the advances and breakthroughs in Nephrology made especially in the past few years.

The course will cover various aspects of nephrology divided into six subtopics, A) Advances in nephrology in 2020, B) Glomerulonephritis, C) End stage kidney disease, D) Acute kidney injury, E) Chronic kidney disease, and F) Transplantation, spread over two days, focusing on hot topics that are likely to have impact on clinical practice. Its target audience are nephrologists, clinicians, fellows and trainees, both locally and internationally. Speakers consist of a mixture of clinicians, researchers and trialists who are experts in their field, with a strong emphasis on translational medicine useful in day-to-day clinical practice.

At the end of the course, participants are expected to have

  1. A snapshot on the most recent published literature in Nephrology,
  2. Enhanced knowledge and understanding in various aspects of nephrology, and
  3. Identify gap in evidence hence promoting future research.


0730 Update Course Registration


At the dawn of 2020, Nephrology fields have made several breakthroughs that include but not limited to the followings: 1) After nearly two decades, a new agent, sodium–glucose cotransporter 2 (SGLT2) inhibitor is proven to prevent loss of kidney function, end-stage kidney disease, hospitalization for heart failure and cardiovascular death in patients with diabetic kidney disease; 2) New discovery has provided an approved treatment to slow the growth of cysts and to preserve kidney function of the most common inherited kidney disease, Autosomal dominant polycystic kidney disease (ADPKD), 3) Several milestones have been made in management of anemia in chronic kidney disease with emerging efficacy and safety evidence of orally available HIF-1a stabilizers, 4). Technical advances in genome sequencing and association studies have yielded critical insights into the genetic architecture of kidney diseases that improve our understanding of the mechanisms of kidney development, homeostasis and disease states, many of which have clinical implications.

Learning objective(s):

  • To promote understanding and clinical knowledge in the recent advances in the field of nephrology.
  • To outline the current available evidence and gaps in knowledge with the view to promote future research.
0800-0830 Advance in Management of DKD
Meg Jardine
0830-0900 Advance in management of anemia in CKD
Simon Roger

Professor Roger is a Consultant Nephrologist and Director at the Renal Unit, Gosford Hospital, Gosford, Australia.  He trained initially at Westmead Hospital in Sydney, then researched at St Bartholomew’s Hospital, London, subsequently   receiving his Doctorate of Medicine degree from the University of New South Wales, Australia.  Professor Roger now has over 30 years’ experience researching anaemia and the role of iron in patients with chronic kidney disease. Full biography

0900-0930 Advances in genetics in clinical nephrology
Amali Mallawaarachchi

Dr Mallawaarachchi is a Clinical Geneticist and Nephrologist, and Staff Specialist at Royal Prince Alfred Hospital, Sydney.  Dr Mallawaarachchi is also a Senior Research Scientist in the Division of Genomics and Epigenetics at the Garvan Institute of Medical Research.  Her current research focuses on understanding the molecular basis of polycystic kidney disease and is supported by a Viertel Foundation Clinical Investigator Award and The PKD Foundation. She has particular expertise in genomic analysis and variant interpretation and developed with first validated whole-genome sequencing based genetic testing for polycystic kidney disease.

0930-1000 Breakthrough in management of PKD – ADPKD and ARPKD
Lisa M. Guay-Woodford

Dr. Lisa M. Guay-Woodford is the McGehee Joyce Professor of Pediatrics at the Children’s National Medical Center (CNMC), a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Full biography

1000-1030 Morning Tea Break

The burden of premature death and health loss from end stage kidney disease (ESKD) is well known. Managing individuals on either haemodialysis or peritoneal dialysis remains a major challenge to the Nephrology community. This session will cover updates in various aspects relating to ESKD including dialysis access, treatment intensity of haemodialysis and regional differences in peritoneal dialysis.

Learning objective(s):

  • To promote understanding and clinical knowledge in the management of ESKD and access.
  • To outline the current available evidence and gaps in knowledge with the view to promote future research directions.
1030-1100 Dose and frequency of dialysis – which is more important?
Lorraine Kwan (APCN)

Lorraine works as associate consultant in the Department of Medicine, in Queen Mary Hospital and Tung Wah Hospital in Hong Kong. She is also honorary tutor at the Li Ka Shing Faculty of Medicine, the University of Hong Kong.  Dr. Kwan received her medical degree from the University of Hong Kong in 2007 and pursued post-graduate training in nephrology in Queen Mary Hospital. Full biography

1100-1130 Update in access in 2020
Andrea Vercelli

Dr Andrea Viecelli is a Senior Lecturer at the Faculty of Medicine, University of Queensland and nephrologist at Princess Alexandra Hospital in Brisbane, Australia.  She completed her PhD on strategies to improve vascular access outcomes in patients on haemodialysis through the University of Queensland in 2019. She is a clinical trialist of the Australasian Kidney Trials Network and a lead investigator of the FAVOURED study, an international, multicentre randomised controlled trial of fish oil and aspirin for preventing arteriovenous fistula failure. Full biography


1130-1200 Update in peritoneal dialysis
Sunita Bavanandan (APCN)

Dr.Sunita Bavanandan graduated from the University of Queensland Australia in December, 1991. She obtained her qualifications as a Member of the Royal College of Physicians United Kingdom in 1997 and  became a Fellow of the Royal College of Physicians Edinburgh in 2007. From 2003-2004 she obtained further training at the Leicester General Hospital, United Kingdom. Special interests are in Chronic Kidney Disease, Hypertension, Diabetic Kidney Disease and Peritoneal  Dialysis. Full biography

1200-1300 Lunch Break


Despite regional difference, glomerulonephritis accounts for nearly a quarter of all cases of chronic kidney disease worldwide. It remains one of the leading cause of end stage kidney disease. Over the past decades, significant advances have been made in the management of glomerulonephritis especially in IgA nephropathy, focal segmental glomerulosclerosis, and ANCA-associated glomerulonephritis. However, several controversies remain in the best practice treatment for these common forms of kidney disease. This session will cover some of the advances in treatment and controversies for glomerulonephritis in 2020.  

Learning objective(s):

  • To promote understanding and clinical knowledge in the management of glomerulonephritis.
  • To outline the current available evidence and gaps in knowledge with view to promote future research directions.
1300-1330 Role of endothelin receptor antagonist in proteinuric kidney disease
Muh Geot Wong

Dr Wong obtained his MBBS in 2000 follows by MRCP (UK) and Nephrology training in Malaysia before migrating to Australia where he obtained his Fellowship in Nephrology and a PhD in Medicine from the University of Sydney in 2010.  He is currently a Renal Staff Specialist at the Royal North Shore Hospital (RNSH), and a Senior Clinical Lecturer of University of Sydney and University of NSW. Full biography

1330-1400 Novel therapy in IgA nephropathy
Yusuke Suzuki (APCN)

Yusuke Suzuki is currently Professor of Department of Nephrology in Graduate School of Juntendo University. His academic positions include Directors of Japanese Society of Nephrology (JSN), Councilor of Japanese Society of Internal Medicine, Japanese Society of Dialysis Therapy, Japanese Society of Hypertension, ISN council, ISN Deputy Chair of North and East Asia Regional Board, Liaison officer in ISN sister renal center program for JSN/Vietnam, Chief Researcher of Special Research Group of IgA Nephropathy in Progressive Renal Diseases Research from the Ministry of Health, Labor and Welfare of Japan, Chief Researcher of biomarker project on IgA nephropathy from Research on Intractable Disease from Japan Agency for Medical Research and Development. Full biography

1400-1430 Update in management of ANCA vasculitis
Steven Yew
1430-1500 Afternoon Tea Break

Recent epidemiological and mechanistic studies suggest that chronic kidney disease and acute kidney injury are closely interconnected — acute kidney injury is increasingly recognised as a risk factor for chronic kidney disease. This session will cover the recent advances in AKI covering broad aspects from intravenous fluid replacement, cardiorenal syndrome and long term sequelae of AKI.

Learning objective(s):

  • To promote understanding and clinical knowledge in the advances in CKD and AKI.
  • To outline the current available evidence and gaps in knowledge with view to promote future research directions.
1500-1530 Is sodium chloride the best replacement fluid?
Michael Collins
1530-1600 Long term sequelae of acute kidney injury
Emily See

Emily See is a Critical Care Nephrologist and Research Fellow in the Department of Intensive Care at Austin Health, Melbourne. She completed her renal training at University Hospital Geelong, Princess Alexandra Hospital, and Monash Health, and is currently undertaking a PhD examining the long-term sequelae of acute kidney injury, with the aim of developing an evidence-based model of care for high-risk survivors.  Full biography

1600-1630 Decision-making for ESRD in the elderly
Rajesh Raj

Rajesh is a Nephrologist trained in India. He moved to Launceston in 2009 and established the renal supportive care service at the Launceston General Hospital in 2011. Full biography



Join other update course participants and our theme sponsors for 30 minutes of small group networking meets and greets.  Each virtual meeting is 5 minutes in length, then you will be randomly reallocated to another group.  A great way to catch up with old friends and meet new colleagues!



0730 Update Course Registration

Management of CKD and its complications remain on-going challenges for nephrologists. This session will cover topics including advances in imagining in management of CKD, use of binders in CKD, including an innovative way of learning electrolytes.

Learning objective(s):

  • To promote understanding and clinical knowledge in the diagnosis and management of chronic kidney disease.
  • To outline the current available evidence and gaps in knowledge with view to promote future research directions.
0800-0830 Role of potassium and uremic binder in management of CKD
Suet-Wan Choy

Dr Suet-Wan Choy completed her medical degree at Melbourne University with honours.  She is a Nephrologist, General Physician and an Obstetric Medicine Physician with public clinical appointments at Austin Health, Eastern Health and the Mercy Hospital for Women.

After completing her PhD at the Austin Hospital, University of Melbourne, Suet-Wan undertook a post-doctoral research fellowship at the Pittsburgh Center for Kidney Research, Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA.

0830-0900 Diagnosis and management of cardiorenal sydnrome
Nathan Dwyer
0900-0930 Advances in imaging in CKD
Patrick Mark

Patrick (Paddy) Mark is Professor of Nephrology and Honorary Consultant Nephrologist at the Glasgow Renal and Transplant Unit based at the Queen Elizabeth University Hospital Glasgow. He was appointed as Clinical Senior Lecturer in 2011 following clinical training in Medicine and Nephrology combined with a Clinical Lecturer post between 2006-2011. He was promoted to Reader in 2015 and to Professor in 2018. He leads the United Kingdom Cardio-Renal Clinical Study Group, as part of the United Kingdom Kidney Research Consortium. Full biography

0930-1000 New ways to learn electrolyte and acid base
Amanda Mather
1000-1030 Morning Tea Break
THEME TSANZ-ANZSN combined TRANSPLANTATION session “What did we learn in kidney transplantation in 2020?”

Kidney transplantation is considered the treatment of choice for individuals with severe chronic kidney disease due to improved quality of life and survival when compared to individuals receiving dialysis. This half-day session is a combined effort of TSANZ and ANZSN in providing an essential updates on relevant topics for non-transplant nephrologists. This session covers relevant topics in kidney transplantation for donor and recipient perspective, from pre-transplant assessment to post-transplant management as well as the paired kidney exchange program. 

Learning objective(s):

  • To promote understanding and clinical knowledge in advances in kidney transplantation for non-transplant physicians.
  • To outline the current available evidence and gaps in knowledge with view to promote future research directions.
1030-1100 Pre-transplant Immunological assessment and management
Natasha Rogers
1100-1130 Frailty in kidney transplantation – when to say no?
Wai Lim
1130-1200 Pre-transplant management of overweight/obesity in potential kidney recipient
Amanda Robertson
1200-1230 Controversies in living donation/high risk kidney donation
To be advised
1230-1330 Lunch Break
THEME TSANZ-ANZSN combined TRANSPLANTATION session “What did we learn in kidney transplantation in 2020?” – continued
1330-1400 Acute and chronic antibody mediated rejection – what should you know?
Susan Wan
1400-1430 Post-transplant recurrence of primary disease including AHUS
Steve Chadban
1430-1500 Kidney transplant histology 101
Brian Nankivell
1500-1530 Paired kidney exchange program review
Stella McGinn
1530-1600 Afternoon Tea Break
1600 Course concludes


The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd